Literature DB >> 11516876

Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation.

L Portelance1, K S Chao, P W Grigsby, H Bennet, D Low.   

Abstract

PURPOSE: The emergent use of combined modality approach (chemotherapy and radiation therapy) for the treatment of patients with cervical cancer is associated with significant gastrointestinal and genitourinary toxicity. Intensity-modulated radiation therapy (IMRT) has the potential to deliver adequate dose to the target structures while sparing the normal organs and could also allow for dose escalation to grossly enlarged metastatic lymph node in pelvic or para-aortic area without increasing gastrointestinal/genitourinary complications. We conducted a dosimetric analysis to determine if IMRT can meet these objectives in the treatment of cervical cancer. METHODS AND MATERIALS: Computed tomography scan studies of 10 patients with cervical cancer were retrieved and used as anatomic references for planning. Upon the completion of target and critical structure delineation, the imaging and contour data were transferred to both an IMRT planning system (Corvus, Nomos) and a three-dimensional planning system (Focus, CMS) on which IMRT as well as conventional planning with two- and four-field techniques were derived. Treatment planning was done on these two systems with uniform prescription, 45 Gy in 25 fractions to the uterus, the cervix, and the pelvic and para-aortic lymph nodes. Normalization was done to all IMRT plans to obtain a full coverage of the cervix with the 95% isodose curve. Dose-volume histograms were obtained for all the plans. A Student's t test was performed to compute the statistical significance.
RESULTS: The volume of small bowel receiving the prescribed dose (45 Gy) with IMRT technique was as follows: four fields, 11.01 +/- 5.67%; seven fields, 15.05 +/- 6.76%; and nine fields, 13.56 +/- 5.30%. These were all significantly better than with two-field (35.58 +/- 13.84%) and four-field (34.24 +/- 17.82%) conventional techniques (p < 0.05). The fraction of rectal volume receiving a dose greater than the prescribed dose was as follows: four fields, 8.55 +/- 4.64%; seven fields, 6.37 +/- 5.19%; nine fields, 3.34 +/- 3.0%; in contrast to 84.01 +/- 18.37% with two-field and 46.37 +/- 24.97% with four-field conventional technique (p < 0.001). The fractional volume of bladder receiving the prescribed dose and higher was as follows: four fields, 30.29 +/- 4.64%; seven fields, 31.66 +/- 8.26%; and nine fields, 26.91 +/- 5.57%. It was significantly worse with the two-field (92.89 +/- 35.26%) and with the four-field (60.48 +/- 31.80%) techniques (p < 0.05).
CONCLUSION: In this dosimetric study, we demonstrated that with similar target coverage, normal tissue sparing is superior with IMRT in the treatment of cervical cancer.

Entities:  

Mesh:

Year:  2001        PMID: 11516876     DOI: 10.1016/s0360-3016(01)01664-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  90 in total

1.  Combination of irinotecan and 5-fluorouracil with radiation in locally advanced rectal adenocarcinoma.

Authors:  Hanan Ahmed Wahba; Hend Ahmed El-Hadaad; Sameh Roshdy
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 2.  Volumetric modulated arc therapy: a review of current literature and clinical use in practice.

Authors:  M Teoh; C H Clark; K Wood; S Whitaker; A Nisbet
Journal:  Br J Radiol       Date:  2011-11       Impact factor: 3.039

Review 3.  The role of imaging in the management of non-metastatic cervical cancer.

Authors:  Orit Kaidar-Person; Roxolyana Bortnyak-Abdah; Amnon Amit; Alison Berniger; Rahamim Ben-Yosef; Abraham Kuten
Journal:  Med Oncol       Date:  2012-04-25       Impact factor: 3.064

4.  The effect of uterine motion and uterine margins on target and normal tissue doses in intensity modulated radiation therapy of cervical cancer.

Authors:  J J Gordon; E Weiss; O K Abayomi; J V Siebers; N Dogan
Journal:  Phys Med Biol       Date:  2011-04-13       Impact factor: 3.609

5.  The change of response of ionization chambers in the penumbra and transmission regions: impact for IMRT verification.

Authors:  D González-Castaño; J Pena; F Sánchez-Doblado; G H Hartmann; F Gómez; A Leal
Journal:  Med Biol Eng Comput       Date:  2007-09-08       Impact factor: 2.602

Review 6.  Current opinion in cervix carcinoma.

Authors:  Silvia Rodríguez Villalba; Carmen Díaz-Caneja Planell; José Manuel Cervera Grau
Journal:  Clin Transl Oncol       Date:  2011-06       Impact factor: 3.405

7.  NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer.

Authors:  Akila N Viswanathan; Jennifer Moughan; Brigitte E Miller; Ying Xiao; Anuja Jhingran; Lorraine Portelance; Walter R Bosch; Ursula A Matulonis; Neil S Horowitz; Robert S Mannel; Luis Souhami; Beth A Erickson; Kathryn A Winter; William Small; David K Gaffney
Journal:  Cancer       Date:  2015-04-06       Impact factor: 6.860

8.  Radiation colitis and proctitis.

Authors:  Gregory D Kennedy; Charles P Heise
Journal:  Clin Colon Rectal Surg       Date:  2007-02

9.  Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementation.

Authors:  Katrien Vandecasteele; Wilfried De Neve; Werner De Gersem; Louke Delrue; Leen Paelinck; Amin Makar; Valérie Fonteyne; Carlos De Wagter; Geert Villeirs; Gert De Meerleer
Journal:  Strahlenther Onkol       Date:  2009-12       Impact factor: 3.621

10.  MRI assessment of cervical cancer for adaptive radiotherapy.

Authors:  Johannes C A Dimopoulos; Gertrude Schirl; Anja Baldinger; Thomas H Helbich; Richard Pötter
Journal:  Strahlenther Onkol       Date:  2009-05-15       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.